Neal D. Shore, MD, on New Data on the Safety and Efficacy of Darolutamide in Patients With Prostate Cancer

Posted: Wednesday, March 8, 2023

Neal D. Shore, MD, of Carolina Urologic Research Center/GenesisCare discusses findings from the ARAMIS Rollover study on the use of darolutamide, a second-generation androgen receptor inhibitor, in patients with nonmetastatic castration-resistant prostate cancer. Dr. Shore reviews the safety and tolerability of this treatment, the durability of outcomes, as well as preventing or managing adverse events.

---